A. Perelló Martorell
Hospital Universitario Son Espases(ES)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER+) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer(2017)6 cited
- → 155TiP A randomised phase II trial of neoadjuvant multi-agent chemotherapy (CHT) OR patritumab deruxtecan (HER3-DXd; U3-1402) +/- endocrine therapy (ET) for high-risk hormone receptor-positive (HR+/HER2-) early breast cancer (EBC): SOLTI-2103 VALENTINE trial(2023)6 cited
- → 130TiP SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype(2021)3 cited
- → 197P ATREZZO trial (SOLTI-1907): A phase II trial targeting estrogen receptor negative or PAM50 non-luminal disease with atezolizumab in combination with trastuzumab and vinorelbine in HER2-positive (HER2+) advanced breast cancer (ABC) - Interim analysis(2023)2 cited
- → 208TiP SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician’s choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial(2022)2 cited
- → Abstract OT1-12-09: Time and motion study of a subcutaneous fixed-dose combination of pertuzumab and trastuzumab for the treatment of patients with HER2-positive early breast cancer (PHaTiMa)(2022)1 cited
- → 116P Time and motion randomised study of a subcutaneous (SC) pertuzumab and trastuzumab fixed-dose combination (PH FDC) for the treatment of HER2-positive early breast cancer (HER2 EBC): PHaTiMa(2023)1 cited
- → Experience with Eribulin in Patients with Metastatic Breast Cancer and Associated Hepatic Impairment: Case Studies(2018)1 cited
- → AGATA molecular screening program: Implementing precision medicine in patients with advanced breast cancer in Spain(2017)1 cited
- → 130P Palbociclib in combination with letrozole in HR+/HER2- residual disease after standard neoadjuvant chemotherapy: Primary results of the SOLTI1710 PROMETEO II window of opportunity trial(2023)